Yttrium-90 (Y90) DOTATATE is a form of targeted internal radiotherapy used in the treatment of certain types of neuroendocrine tumours. It involves the use of a radioactive isotope called Yttrium-90, which is attached to a molecule called DOTATATE. This molecule specifically targets and binds to somatostatin receptors, which are often found in high numbers on the surface of neuroendocrine tumour cells.
The radioactive properties of yttrium-90 allow it to deliver radiation directly to the tumour cells, while minimizing damage to surrounding healthy tissues. The emitted radiation from yttrium-90 can penetrate a short distance into the tumour, delivering a high dose of radiation to the targeted cells.